UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~October~~December 54, 2023

ENDONOVO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

000-55453

45-2552528

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

6320 Canoga Avenue, 15^thFloor

Woodland Hills, CA 91367

(Address of principal executive office)(Zip Code)

Registrant’s telephone number, including area code: (800) 489-4774

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 81.01 ~~Other~~Entry ~~Events~~into a Material Definitive Agreement.

On ~~October~~December 103, 2023, the Company ~~was~~entered ~~advised~~into bya ~~Evermed~~definitive Asset Purchase Agreement with SofPulse, ~~its~~Inc., ~~distributor~~a inDelaware ~~Taiwan~~corporation ("SPI"), ~~that~~to acquire the ~~Taiwan~~SofPulse® ~~Food~~Assets ~~and~~which ~~Drug~~represents ~~Administration~~the ~~had~~technology, ~~granted~~both patented and proprietary, inventories aand ~~license~~contract rights relating to the Company’'s SofPulse® Electroceutical® device ~~for~~as it relates to medical use. The Company has retained rights to the non-medical applications of SofPulse® and will continue the development of its tele-health business. The purchase price under the Asset Purchase Agreement shall be no less then $50 Million and shall be fixed to equal the amount of a third party evaluation of the SofPulse® Assets which will be completed before the closing under the Asset Purchase Agreement. $50 Million of the purchase price for the SofPulse® Assets will be paid by the issuance of SPI stock to the Company tentatively valued at $5 a share but to be adjusted to be equal to the per share price in ~~Taiwan~~SPI's IPO (which may or may not ever occur) and the balance to be in the form of cash or note. The ~~original~~Closing ~~license~~under the Asset Purchase Agreement is subject to shareholder approval by the Company and other conditions.The foregoing is only a ~~translation~~summary ~~are~~of the Asset Purchase Agreement and the reader is ~~included~~referred asto the agreement, which is an exhibit to this report for its full terms and conditions.

Item 9.01 Financial Statements and Exhibits.

(a)

Financial Statements

None

(b)

Exhibits

	99.1	Taiwan License and translation
	10.1	Asset Purchase Agreement
	104	Cover Page Interactive Data File (~~the cover page XBRL tags are~~ embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: ~~October~~December 124, 2023

	ENDONOVO THERAPEUTICS, INC.

	By:	/s/ Alan Collier
		Alan Collier
		Chief Executive Officer

Filing Compare · ENDONOVO THERAPEUTICS, INC.